natgillin/translations-raw huggingface dataset:
During use or when carried as a spare: NovoMix 50 Penfill that is being used or carried as a spare should not be kept in the refrigerator. 
Med uporabo in ko zdravilo uporabljate kot rezervo: zdravila NovoMix 50 Penfill, ki ga uporabljate ali ga imate pri sebi za rezervo, ne shranjujte v hladilniku.
Before opening: NovoMix 30 Penfill that is not being used must be stored in the refrigerator at 2°C to 8°C, away from the cooling element. 
Pred odprtjem: zdravilo NovoMix 30 Penfill, ki ga ne uporabljate, shranjujte v hladilniku pri temperaturi 2 °C - 8 °C in ne blizu hladilnega elementa.
How to store NovoMix 50 
Shranjevanje zdravila NovoMix 50
12 units Residual scale 
12 enot merilo preostanka igla (primer)
Before opening: NovoMix 50 Penfill that is not being used must be stored in the refrigerator at 2°C to 8°C, away from the cooling element. 
Pred odprtjem: zdravilo NovoMix 50 Penfill, ki ga ne uporabljate, shranjujte v hladilniku pri temperaturi 2 °C - 8 °C in ne blizu hladilnega elementa.
► Inject the insulin under your skin. 
Kako injicirati zdravilo NovoMix 30 ► Insulin injicirajte pod kožo.
1 ml suspension contains 100 units soluble insulin aspart/protamine-crystallised insulin aspart in the ratio 30/70 (equivalent to 3.5 mg). 
1 ml suspenzije vsebuje 100 enot topnega insulina aspart/s protaminom kristaliziranega insulina aspart v razmerju 30/70 (kar ustreza 3,5 mg),
1 ml suspension contains 100 units soluble insulin aspart/protamine-crystallised insulin aspart in the ratio 70/30 (equivalent to 3.5 mg). 
1 ml suspenzije vsebuje 100 enot topnega insulina aspart/s protamin kristaliziranega insulina aspart v razmerju 70/30 (kar ustreza 3,5 mg),
NovoMix 30 is for subcutaneous administration only. 
Zdravilo NovoMix 30 je namenjeno zgolj subkutani uporabi.
How to store NovoMix 70 
Shranjevanje zdravila NovoMix 70
What you need to know before you use NovoMix 30 
Kaj morate vedeti, preden boste uporabili zdravilo NovoMix 30 Ne uporabljajte zdravila NovoMix 30:
How to store NovoMix 30 
Shranjevanje zdravila NovoMix 30
1 ml of the suspension contains 100 units soluble insulin aspart*/protamine-crystallised insulin aspart* in the ratio 30/70 (equivalent to 3.5 mg). 
1 ml suspenzije vsebuje 100 enot topnega insulina aspart*/s protaminom kristaliziranega insulina aspart* v razmerju 30/70 (kar ustreza 3,5 mg).
1 x 3 ml pre-filled pen 
5 x 3 ml vložek
1 ml of the suspension contains 100 units soluble insulin aspart*/protamine-crystallised insulin aspart* in the ratio 70/30 (equivalent to 3.5 mg). 
1 ml suspenzije vsebuje 100 enot topnega insulina aspart*/s protaminom kristaliziranega insulina aspart* v razmerju 70/30 (kar ustreza 3,5 mg).
Patients transferred to NovoMix 70 from another type of insulin may require an increased number of daily injections or a change in dose from that used with their usual insulin medicinal products. 
Bolniki, ki preidejo na zdravilo NovoMix 70 z druge vrste insulina,
NAME OF THE MEDICINAL PRODUCT NovoMix 50 Penfill 100 units/ml 
IME ZDRAVILA IN POT UPORABE NovoMix 50 Penfill 100 enot/ml suspenzija za injiciranje
Pack sizes of 1, 5 and 10 pre-filled pens of 3 ml. 
Pakiranja z 1, 5 in 10 vložki po 3 ml. Na trgu morda ni vseh navedenih pakiranj.
Patients transferred to NovoMix 50 from another type of insulin may require an increased number of daily injections or a change in dose from that used with their usual insulin medicinal products. 
Bolniki, ki preidejo na zdravilo NovoMix 50 z druge vrste insulina,
If any of these apply, do not use NovoMix 50. 
Kaj morate vedeti, preden boste uporabili zdravilo NovoMix 50 Ne uporabljajte zdravila NovoMix 50:
NovoMix 70 Penfill is designed to be used with Novo Nordisk insulin delivery systems and NovoFine or NovoTwist needles. 
Apliciranje s sistemom za dajanje insulina Zdravilo NovoMix 70 Penfill je namenjeno za uporabo v sistemih za dajanje insulina Novo Nordisk in iglami NovoFine ali NovoTwist.
The review of Protelos/Osseor was initiated in May 2013 at the request of European Commission under Article 20 of Regulation (EC) No 726/2004. 
Pregled zdravila Protelos/Osseor se je začel maja 2013 na zahtevo Evropske komisije v skladu s členom 20 Uredbe (ES) št. 726/2004.
• If you have any questions, speak to your doctor or pharmacist. 
• Če imate dodatna vprašanja, se posvetujte z zdravnikom ali farmacevtom.
Importantly, the company is required to conduct further research to demonstrate the effectiveness of the new measures. 
Pomembno je, da družba izvede dodatne raziskave, s katerimi bo potrdila učinkovitost novih ukrepov.
The results showed an increased risk of myocardial infarction with Protelos/Osseor as compared with placebo (1.7% versus 1.1 %), with a relative risk of 1.6 (95% CI, 1.07 to 2.38), and an increased risk of venous thrombotic and embolic events - 1.9% versus 1.3 % with a relative risk of 1.5 (95% CI, 1.04 to 2.19). 
Rezultati so pokazali povečano tveganje za miokardni infarkt pri uporabi zdravila Protelos/Osseor v primerjavi s placebom (1,7 % v primerjavi z 1,1 %) z relativnim tveganjem 1,6 (95-odstotni IZ, 1,07 do 2,38) in povečano tveganje za venske trombotične in embolične dogodke1,9 % v primerjavi z 1,3 %, z relativnim tveganjem 1,5 (95-odstotni IZ, 1,04 do 2,19).
Protelos/Osseor to remain available but with further restrictions 
Zdravilo Protelos/Osseor bo še naprej na voljo, vendar z dodatnimi omejitvami
'The PRAC will continue to monitor the safety of Protelos /Osseor and the effectiveness of risk minimisation in long term use.' 
„Odbor PRAC bo še naprej spremljal varnost zdravila Protelos/Osseor ter učinkovitost ukrepov za zmanjšanje tveganja pri dolgotrajni uporabi.“
In addition, patients treated with Protelos/Osseor should be screened and monitored regularly, every 6 to 12 months. 
Poleg tega je treba bolnike, ki se zdravijo z zdravilom Protelos/Osseor, redno spremljati in pregledovati na vsakih 6 do 12 mesecev.
It is also used to treat severe osteoporosis in men who are at high risk of fracture. 
Prav tako se uporablja za zdravljenje hude osteoporoze pri moških z velikim tveganjem za zlome.
'However, the CHMP considered that, for patients who have no alternative treatment, regular screening and monitoring to exclude cardiovascular disease will sufficiently reduce the risk identified by the PRAC so that these patients can continue to have access to the medicine.' 
„Vendar je odbor CHMP menil, da bo pri bolnikih, ki nimajo nobene druge možnosti zdravljenja, redno pregledovanje in spremljanje za izključitev srčno-žilnih bolezni zadostno zmanjšalo tveganje, ki ga je ugotovil odbor PRAC, da lahko zdravilo za te bolnike ostane še naprej dostopno.“
• Before starting treatment, your doctor will assess your risk of heart disease and high blood pressure and continue to check your risk at regular intervals during treatment. 
• Pred začetkom zdravljenja bo zdravnik ocenil, kakšno je vaše tveganje za bolezni srca in visok krvni tlak, ter tveganje nato ocenjeval v rednih časovnih presledkih tudi med zdravljenjem.
The patient's risk of developing cardiovascular disease should be evaluated before starting treatment and on a regular basis thereafter, generally every 6 to 12 months; 
Tveganje za razvoj srčno-žilne bolezni pri bolniku je treba oceniti pred začetkom zdravljenja in nato še v rednih časovnih presledkih, praviloma na vsakih 6 do 12 mesecev.
'The PRAC has worked closely with the CHMP throughout the procedure and while we acknowledge that the recommendations of the two committees differed, our understanding of the medicine's benefit-risk profile is closely aligned and we share a common view of the importance of effective monitoring of cardiovascular risk', said June Raine, chair of the PRAC. 
„Odbor PRAC je med celotnim postopkom tesno sodeloval z odborom CHMP in čeprav se zavedamo, da se priporočila obeh odborov razlikujejo, je naše razumevanje razmerja med tveganji in koristmi zdravila zelo usklajeno, imamo pa tudi enako mnenje o pomembnosti učinkovitega spremljanja srčno-žilnega tveganja,“ je dejala June Raine, predsednica odbora PRAC.
The CHMP opinion was forwarded to the European Commission, which endorsed it and issued a final legally binding decision valid throughout the EU on 15 April 2014. 
Odbor CHMP je mnenje predložil Evropski komisiji, ki ga je potrdila in 15. aprila 2014 izdala končni pravno zavezujoči sklep, ki velja za celotno EU.
In addition these patients should continue to be evaluated regularly by their doctor and treatment should be stopped if patients develop heart or circulatory problems, such as uncontrolled high blood pressure or angina. 
Poleg tega morajo zdravniki te bolnike še naprej redno spremljati in zdravljenje prekiniti, če se pri njih pojavijo težave s srcem ali ožiljem, na primer nenadzorovan visok krvni tlak ali angina.
Additional risk minimisation measures include providing educational material to prescribers to ensure that only the appropriate patients are treated with the medicine. 
Dodatni ukrepi za zmanjšanje tveganja vključujejo razdelitev izobraževalnega gradiva zdravstvenim delavcem, ki predpisujejo to zdravilo, da se zagotovi, da se bo uporabljalo samo pri ustrezni skupini bolnikov.
Both committees worked in close collaboration and the PRAC's recommendation was instrumental for us to fully assess the benefit-risk profile of the medicine', said Tomas Salmonson, chair of the CHMP. 
Odbora sta pri svojem delu tesno sodelovala, priporočilo odbora PRAC pa je bilo ključno za našo celovito oceno razmerja med tveganji in koristmi zdravila,“ je dejal Tomas Salmonson, predsednik odbora CHMP.
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom should remain an option for patients with no history of cardiovascular disease who cannot take other medicines. 
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom velikim tveganjem, zaključil, da mora zdravilo Protelos/Osseor ostati dostopno bolnikom, ki v anamnezi nimajo srčno-žilnih bolezni in ne morejo uporabljati drugih zdravil.
In deciding on how Protelos/Osseor should be used, the CHMP took into account the PRAC's analysis of its benefits and risks as well as advice from osteoporosis experts that there is a group of patients who could benefit from the medicine. 
Pri sprejemanju odločitve glede uporabe zdravila Protelos/Osseor je odbor CHMP upošteval analizo koristi in tveganj, ki jo je izvedel odbor PRAC, ter mnenje strokovnjakov za osteoporozo, da obstaja skupina bolnikov, ki bi jim zdravilo lahko koristilo.
This final EMA recommendation on the use of Protelos/Osseor was based on an analysis of pooled data from randomised studies in around 7,500 post-menopausal women with osteoporosis. 
To končno priporočilo Evropske agencije za zdravila glede uporabe zdravila Protelos/Osseor temelji na analizi združenih podatkov iz randomiziranih študij pri približno 7 500 ženskah po menopavzi, ki so imele osteoporozo.
• Doctors should continue to base their decision to prescribe Protelos/Osseor on an assessment of the individual patient's risks. 
• Odločitev zdravnikov, ali bodo predpisali zdravilo Protelos/Osseor, mora še naprej temeljiti na oceni tveganj za posameznega bolnika.
The PRAC's recommendations were then sent to the Committee for Medicinal Products for Human Use (CHMP) responsible for all questions concerning medicines for human use, which adopted the Agency's final opinion. 
Priporočila je nato posredoval Odboru za zdravila za uporabo v humani medicini (CHMP), pristojnemu za vsa vprašanja, povezana z zdravili za uporabo v humani medicini, ki je sprejel končno mnenje agencije.
Regarding the benefits, the efficacy data showed an effect in preventing fractures, including in patients at high risk of fracture. 
Kar zadeva koristi zdravila, so podatki o učinkovitosti pokazali učinek pri preprečevanju zlomov, med drugim tudi pri bolnikih z velikim tveganjem za zlome.
Protelos/Osseor (strontium ranelate) is authorised in the EU to treat severe osteoporosis (a disease that makes bones fragile) in women who have been through the menopause and who are at high risk of fracture (broken bones) to reduce the risk of fractures of the spine and the hip. 
Zdravilo Protelos/Osseor (stroncijev ranelat) je v EU odobreno za zdravljenje hude osteoporoze (bolezni, ki povzroča krhkost kosti) pri ženskah, pri katerih je že nastopila menopavza in pri katerih obstaja veliko tveganje za zlome (zlomljene kosti), da se zmanjša tveganje za zlome hrbtenice in kolka.
The CHMP's recommendations were sent to the European Commission, which endorsed them and issued a final legally binding decision valid throughout the EU. 
Odbor CHMP je priporočila predložil Evropski komisiji, ki jih je potrdila in izdala končni pravno zavezujoči sklep, ki velja za celotno EU.
The first stage of this review was conducted by the Pharmacovigilance Risk Assessment Committee (PRAC), the committee responsible for the evaluation of safety issues for human medicines, which made a set of recommendations. 
Prvo fazo pregleda je opravil Odbor za oceno tveganja na področju farmakovigilance (PRAC), ki je odgovoren za presojo varnostnih vprašanj o zdravilih za uporabo v humani medicini, in podal več priporočil.
• Doctors should review their patients currently on Protelos/Osseor as necessary. 
• Zdravniki naj po potrebi ponovno ocenijo zdravljenje pri bolnikih, ki trenutno uporabljajo zdravilo Protelos/Osseor.
• You should not take Protelos/Osseor if you have or have had heart or circulatory problems such as stroke, heart attack, or obstruction of the blood flow in the arteries. 
• Zdravila Protelos/Osseor ne smete uporabljati, če imate ali ste kdaj imeli težave s srcem ali ožiljem, kot so možganska kap, srčna kap ali zapora krvnega pretoka v arterijah.
In arriving at its conclusions, the CHMP noted that study data showed a beneficial effect in preventing fractures, including in patients at high risk of fracture. 
Pri sprejemanju zaključkov je odbor CHMP upošteval, da so podatki iz študij pokazali ugoden učinek pri preprečevanju zlomov, med drugim tudi pri bolnikih z velikim tveganjem za zlome.
'The CHMP agreed with the PRAC's overall assessment of the risks of Protelos/Osseor. 
„Odbor CHMP se je strinjal s splošno oceno tveganj, povezanih z zdravilom Protelos/Osseor, ki jo je podal odbor PRAC.
The current recommendations add to EMA recommendations made in April 2013 not to use Protelos/Osseor in patients with known circulatory problems. 
Sedanja priporočila dopolnjujejo priporočila Evropske agencije za zdravila, sprejeta aprila 2013, z omejitvijo, da se zdravilo Protelos/Osseor ne sme uporabljati pri bolnikih z ugotovljenimi težavami z ožiljem.
The European Medicines Agency has concluded its review of Protelos/Osseor and has recommended further restricting the use of the medicine to patients who cannot be treated with other medicines approved for osteoporosis. 
Evropska agencija za zdravila je zaključila pregled zdravila Protelos/Osseor ter priporočila dodatno omejitev uporabe zdravila, in sicer na bolnike, ki jih ni mogoče zdraviti z drugimi zdravili, odobrenimi za osteoporozo.
These final recommendations from the Agency's Committee for Medicinal Products for Human Use (CHMP) come after initial advice from the Pharmacovigilance Risk Assessment Committee (PRAC) to suspend the medicine due to its cardiovascular risk. 
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je ta končna priporočila izdal, potem ko je Odbor za oceno tveganja na področju farmakovigilance (PRAC) najprej priporočil začasni umik dovoljenja za promet z zdravilom zaradi z njim povezanega srčno-žilnega tveganja.
In addition, available data do not show evidence of an increased cardiovascular risk with Protelos/Osseor in patients who did not have a history of heart or circulatory problems. 
Poleg tega razpoložljivi podatki ne kažejo, da se pri uporabi zdravila Protelos/Osseor poveča srčno-žilno tveganje pri bolnikih, ki v anamnezi niso imeli bolezni srca ali ožilja.
• Protelos/Osseor should only be used to treat severe osteoporosis in postmenopausal women and men at high risk of fracture, for whom treatment with other medicinal products approved for the treatment of osteoporosis is not possible due to, for example, contraindications or intolerance; 
• Zdravilo Protelos/Osseor se lahko uporablja samo za zdravljenje hude osteoporoze pri ženskah po menopavzi in moških z velikim tveganjem za zlome, pri katerih zdravljenje z drugimi zdravili, odobrenimi za zdravljenje osteoporoze, ni mogoče, na primer zaradi kontraindikacij ali intolerance.
• Protelos/Osseor will only be prescribed for preventing fractures in post-menopausal women and men with severe osteoporosis who have a high risk of fracture and cannot be treated with other medicines approved for osteoporosis. 
• Zdravilo Protelos/Osseor se bo predpisovalo samo za preprečevanje zlomov pri ženskah po menopavzi in moških s hudo osteoporozo, pri katerih obstaja veliko tveganje za zlome in jih ni mogoče zdraviti z drugimi zdravili, ki so odobrena za osteoporozo.
The CHMP considered that the cardiovascular risk in patients taking Protelos/Osseor can be managed by restricting its use to patients with no history of heart and circulatory problems and limiting its use to those who cannot take other medicines approved for the treatment of osteoporosis. 
Odbor CHMP je menil, da je srčno-žilno tveganje pri bolnikih, ki uporabljajo zdravilo Protelos/Osseor, mogoče obvladati tako, da se uporaba zdravila omeji na bolnike, ki v anamnezi nimajo bolezni srca in ožilja, ter dodatno na tiste, ki ne morejo uporabljati drugih zdravil, ki so odobrena za zdravljenje osteoporoze.
Available data do not show evidence of an increased cardiovascular risk in patients without established, current or past history of ischaemic heart disease, peripheral arterial disease or cerebrovascular disease, or in those without uncontrolled hypertension. 
Razpoložljivi podatki ne kažejo povečanega srčno-žilnega tveganja pri bolnikih brez ugotovljene obstoječe ali pretekle ishemične bolezni srca, periferne arterijske bolezni in/ali možgansko-žilne bolezni ter pri bolnikih z nenadzorovano hipertenzijo.
• Protelos/Osseor must not be used in patients with established, current or past history of ischaemic heart disease, peripheral arterial disease and/or cerebrovascular disease, or those with uncontrolled hypertension; 
• Zdravilo Protelos/Osseor se ne sme uporabljati pri bolnikih z ugotovljeno obstoječo ali preteklo ishemično boleznijo srca, periferno arterijsko boleznijo in/ali možgansko-žilno boleznijo ter pri bolnikih z nenadzorovano hipertenzijo.
As recommended in a previous review, patients who have a history of certain heart or circulatory problems, such as stroke and heart attack, must not use the medicine. 
V skladu s priporočili iz predhodnega pregleda zdravila ne smejo uporabljati bolniki, ki imajo v anamnezi določene bolezni srca ali ožilja, kot sta možganska in srčna kap.
• Protelos/Osseor should be stopped if the patient develops ischaemic heart disease, peripheral arterial disease or cerebrovascular disease, or if hypertension is uncontrolled; 
• Zdravljenje z zdravilom Protelos/Osseor je treba prekiniti, če se pri bolniku pojavi ishemična bolezen srca, periferna arterijska bolezen ali možgansko-žilna bolezen, ter v primeru nenadzorovane hipertenzije.
The Committee concluded that given the benefits seen in preventing fractures in patients at high risk, Protelos/Osseor 
Odbor je ob upoštevanju koristi, ki so jih opazili pri preprečevanju zlomov pri bolnikih z
• Your treatment with Protelos/Osseor will be stopped if you develop heart or circulatory problems during treatment. 
• Če se bodo med zdravljenjem z zdravilom Protelos/Osseor pri vas pojavile težave s srcem ali ožiljem, bo zdravnik zdravljenje prekinil.
There was also an unvaccinated control group. 
V študijo je bila vključena tudi necepljena kontrolna skupina.
The European Commission granted a marketing authorisation valid throughout the European Union, for Eryseng Parvo on 8 July 2014. 
Evropska komisija je dovoljenje za promet z zdravilom Eryseng Parvo, veljavno po vsej Evropski uniji, izdala 8. julija 2014.
For swine erysipelas two laboratory studies were conducted. 
Za svinjsko rdečico sta bili izvedeni dve laboratorijski študiji.
The most common side effect (seen in more than 1 in 10 pigs) with Eryseng Parvo is mild to moderate inflammation at the injection site which typically resolves within four days but in some cases may persist for up to 12 days post-vaccination. 
Najpogostejši neželeni učinek (opažen pri več kot 1 prašiču od 10) zdravila Eryseng Parvo je blago do zmerno vnetje na mestu injiciranja, ki običajno izzveni v štirih dneh, v nekaterih primerih pa vztraja do 12 dni po cepljenju.
The parvovirus study showed that Eryseng Parvo protected 100% of the foetuses whilst 89% of foetuses were mummified in the control group. 
Študija s parvovirusom je pokazala, da je zdravilo Eryseng Parvo zaščitilo 100 % fetusov, medtem ko je bilo v kontrolni skupini 89 % fetusov mumificiranih.
The Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the benefits of Eryseng Parvo exceed the risks for the approved indication and recommended that Eryseng Parvo be given a marketing authorisation. 
Odbor za zdravila za uporabo v veterinarski medicini (CVMP) je zaključil, da so koristi zdravila Eryseng Parvo večje od z njim povezanih tveganj za odobreno indikacijo, in priporočil izdajo dovoljenja za promet z zdravilom Eryseng Parvo.
Other information about Eryseng Parvo: 
Druge informacije o zdravilu Eryseng Parvo:
Eryseng Parvo is available as a suspension for injection. 
Zdravilo Eryseng Parvo je na voljo v obliki suspenzije za injiciranje.
For porcine parvovirus a laboratory study was conducted involving three groups of 11 gilts (female pigs that have not yet had piglets) vaccinated with different concentrations of porcine parvovirus. 
Za prašičjo parvovirozo je bila izvedena laboratorijska študija, ki je vključevala tri skupine po 11 mladic (prašičjih samic, ki še niso prasile), cepljenih z različnimi koncentracijami prašičjega parvovirusa.
The second laboratory study involved 15 gilts which were vaccinated according to the basic vaccination schedule with a booster dose six months later. 
V drugo laboratorijsko študijo je bilo vključenih 15 mladic, ki so jih cepili v skladu z osnovnim razporedom cepljenja, šest mesecev pozneje pa so prejele še poživitveni odmerek.
The first study involved 40 pigs; 30 pigs were vaccinated with two doses, separated by three weeks, while a control group of 10 pigs received placebo (dummy treatment). 
V prvi študiji, v katero je bilo vključenih 40 prašičev, je bilo 30 prašičev cepljenih z dvema odmerkoma v presledku treh tednov, kontrolna skupina 10 prašičev pa je prejela placebo (zdravilo brez zdravilne učinkovine).
In the future, if the animals are exposed to porcine parvovirus and Erysipelothrix rhusiopathiae bacteria, the immune system will be able to respond more quickly. 
Ob morebitni ponovni izpostavitvi prašičjemu parvovirusu in bakteriji Erysipelothrix rhusiopathiae se bo imunski sistem lahko odzval hitreje.
Pigs were vaccinated with two doses at an interval of three weeks, with the second dose given three to four weeks before mating. 
Cepljene so bile z dvema odmerkoma v presledku treh tednov, pri čemer so drugi odmerek prejele tri do štiri tedne pred parjenjem.
The measure of effectiveness was absence of porcine parvovirus and anti-porcine parvovirus antibodies in the foetuses. 
Merilo učinkovitosti je bila odsotnost prašičjega parvovirusa in protitelesa proti prašičjemu parvovirusu v fetusih.
Eryseng Parvo contains an adjuvant (aluminium hydroxide, DEAE-dextran and ginseng) to enhance the immune response. 
Zdravilo Eryseng Parvo vsebuje tudi adjuvans (aluminijev hidroksid, DEAE-dekstran in ženšen) za povečanje imunskega odziva.
Pigs were challenged with parvovirus at day 40 of pregnancy and then euthanized (humanely killed) at day 90 of pregnancy. 
Samicam so 40. dan brejosti vbrizgali parvovirus, 90. dan brejosti pa so jih evtanazirali (ubili na human način).
Eryseng Parvo is a vaccine. 
Zdravilo Eryseng Parvo je cepivo.